PLAY PODCASTS
If Treatment Supply Is Limited in Future COVID-19 Viral Peaks, How Do We Ethically Prioritize Patients for Treatment?
Episode 240

If Treatment Supply Is Limited in Future COVID-19 Viral Peaks, How Do We Ethically Prioritize Patients for Treatment?

Listen as expert faculty discuss the ethical prioritization of patients for COVID-19 treatment when treatment supplies are limited.

Decera Clinical Education Infectious Disease Podcast · Fernando Carnavali MD, Raska Karnik MS MD, Renslow Sherer MD, Joseph Torrisi PharmD BCIDP

December 29, 20227m 42s

Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

Fernando Carnavali, MD; Rasika Karnik, MS, MD; Renslow Sherer, MD; and Joseph Torrisi, PharmD, BCIDP, discuss how to ethically prioritize patients for COVID-19 treatment when treatment supplies may be limited, including insights on:

  • Risk stratification
  • Medication acquisition
  • Drug interactions

Presenters:

Fernando Carnavali, MD
Associate Professor of Medicine
Division Chief
General Internal Medicine
Department of Medicine
Site Director 
COVID Center of Excellence Satellite-Ansonia 
Mount Sinai Health 
New York, New York

Rasika Karnik, MS, MD
Assistant Professor
Division of Primary Care
Department of Internal Medicine
University of Chicago
Medical Director
Post-COVID Recovery Clinic
Chicago, Illinois

Renslow Sherer, MD
Director
International HIV Training Center
Professor of Medicine
Section of Infectious Diseases and Global Health
Department of Medicine
University of Chicago
Chicago, Illinois

Joseph Torrisi, PharmD, BCIDP
Clinical Pharmacy Specialist
Infectious Diseases 
Pharmacy
Grady Health System
Atlanta, Georgia

Link to slides: 
https://bit.ly/3hXMgId

Link to full program: 
https://bit.ly/3G271KL


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Topics

treatmentdrug shortagehigh riskritonavirnirmatrelvir plus ritonavirpaxlovidcomorbiditiesdrug interactionslimited treatment suppliesrisktreatment shortagehigh-risknirmatrelvir + ritonavirrisk stratificationcovid-19covidomicronnirmatrelvirlimited treatment supplysars-cov-2